Bicara Therapeutics BCAX Weighted Average Exercise Price of Exercisable Options

Weighted Average Exercise Price of Exercisable Options at other companies

NuScale PowerSMR

$3.86-1.0%

Community Financial SystemCBU

$57.10+3.9%

BillionToOne, Inc. BLLN

$7.04—

HTF

Heartflow, Inc. Common StockHTFL

5.6—

Ondas, Inc. ONDS

$3.51-23.7%

TFS FinancialTFSL

$15.81+2.7%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's weighted average exercise price of exercisable options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's weighted average exercise price of exercisable options?: Bicara Therapeutics (BCAX) reported weighted average exercise price of exercisable options of $10.74 in Q1 2026.